
    
      Phase 1b: In the dose escalation portion of the study, various cohorts with escalating doses
      of lenalidomide may be explored, using the 3+3+3 principle for dose determination.

      Phase 2: This will be conducted as an international, multicenter, open-label study. Eligible
      subjects will receive ibrutinib, lenalidomide and rituximab.
    
  